Regeneron Pharmaceuticals Q3 2024 Adj. EPS $12.46 Beats $11.69 Estimate, Sales $3.720B Beat $3.670B Estimate
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals reported Q3 2024 earnings per share of $12.46, surpassing the analyst estimate of $11.69. The company's sales reached $3.720 billion, exceeding the expected $3.670 billion and marking a 10.62% increase from the previous year.
October 31, 2024 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals reported better-than-expected Q3 2024 earnings and sales, with EPS of $12.46 beating estimates by 6.59% and sales of $3.720 billion exceeding expectations by 1.36%.
The positive earnings surprise and sales growth indicate strong financial performance, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100